|
1) Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292: 344-50
|
|
|
|
2) Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380: 435-9
|
|
|
|
|
|
3) Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996; 380: 439-42
|
|
|
|
|
|
4) Bergers G. Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-10
|
|
|
|
|
|
5) Gaillard I, Keramidas M, Liakos P, et al. ACTH-regulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature. J Cell Physiol. 2000; 185: 226-34
|
|
|
|
|
|
6) Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev. 1992; 72: 369-417
|
|
|
|
|
|
7) Blagosklonny MV, An WG, Romanova LY, et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem. 1998; 273: 11995-8
|
|
|
|
|
|
8) Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446: 444-8
|
|
|
|
|
|
9) Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J. 2000; 19: 2537-48
|
|
|
|
|
|
10) Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002; 99: 12333-8
|
|
|
|
|
|
11) Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002; 277: 22896-901
|
|
|
|
|
|
12) Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002; 22: 2799- 809
|
|
|
|
|
|
13) Tsujita Y, Muraski J, Shiraishi I, et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2006; 103: 11946-51
|
|
|
|
|
|
14) Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005; 115: 527-37
|
|
|
|
|
|
15) Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117: 399-412
|
|
|
|
|
|
16) Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem. 2005; 280: 20814-23
|
|
|
|
|
|
17) Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115: 2108-18
|
|
|
|
|
|
18) Brugarolas JB, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003; 4: 147-58
|
|
|
|
|
|
19) Yanazume T, Hasegawa K, Wada H, et al. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem. 2002; 277: 8618-25
|
|
|
|
|
|
20) Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998; 273: 2161-8
|
|
|
|
|
|
21) Hirotani S, Otsu K, Nishida K, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002; 105: 509-15
|
|
|
|
|
|
22) Yamaguchi O, Higuchi Y, Hirotani S, et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A. 2003; 100: 15883-8
|
|
|
|
|
|
23) Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215-28
|
|
|
|
|
|
24) Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998; 281: 1690-3
|
|
|
|
|
|
25) De Windt LJ, Lim HW, Taigen T, et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res. 2000; 86: 255-63
|
|
|
|
|
|
26) van Oort RJ, van Rooij E, Bourajjaj M, et al. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation. 2006; 114: 298-308
|
|
|
|
|
|
27) Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999; 5: 246-7
|
|
|
|
|